my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Genmab A/S announced that its co-founder, Lisa N. Drakeman, Ph.D. retires from her position as Chief Executive Officer of and as member of the board of directors of Genmab. Under her leadership, Genmab raised over USD 1 billion in capital, completed the largest initial public offering of any biote more
Bristol-Myers Squibb Company announced that the initial tender offer, through its wholly owned subsidiary, Puma Acquisition Corporation, for all outstanding shares of common stock of Medarex, Inc. expired at midnight (New York City time) on August 26, 2009, and was not extended. The depositary for more
Bristol-Myers Squibb Company and Medarex, Inc. announced that the companies have signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. The transaction, with an aggregate purchase price of approximately $2.4 billion, has b more
Evaluation of: Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010). Interference with the inhibitory immune regulatory checkpoints that act to constrain overly exuberant immune responses and help to ma more
Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more
Compugen, Ltd. (Compugen) is a biotechnology company engaged in the development, production and marketing of therapeutic and diagnostic biomarker product candidates for cancer, cardiovascular, and immune-related diseases. The company's therapeutic product pipeline includes, cgen-856 and cgen-857, th more
Tularik, Inc. (Tularik) is a pharmaceutical company that is engaged in the discovery and development of oral medicines. The products offered by the company act through the regulation of gene expression. The company is focused on the development of drugs for the treatment of esophageal cancer, gastri more
A A Home About Us Investors Management Board of Directors Scientific Advisory Board Technologies Antibodies Overview Intellectual Property Glossary Partnering Press Room Career Contact Maps & Directions Basel Site Maps & Directions Jena Site Press Room Recent news releases March 16, 2010: 4-Antibody more
Corporate Overview History Management Team Board of Directors Collaborators & Advisors Current Investors Overview Therapeutic Areas Pipeline Publications Press Releases Presentations Careers Press Releases Trillium expands immunology pipeline and enters stem cell field through in-licensing of two ne more
A A Home About Us Investors Management Board of Directors Scientific Advisory Board Technologies Antibodies Overview Intellectual Property Glossary Partnering Press Room Career Contact Maps & Directions Basel Site Maps & Directions Jena Site Management Currently employing 40 staff, 4-Antibody’s pote more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
